Congenital Cardiac Anesthesia Society
A Section of the the Society for Pediatric Anesthesia

Congenital Cardiac Anesthesia Society

  • Member Login
  • Forgot Password?
  • Join
  • Home
  • About
    • Mission Statement
    • Bylaws
    • Board of Directors
    • History
    • Past Presidents
    • Charter Members
    • CCAS Lifetime Achievement Award
    • Mailing List Rental
    • Contact Us
  • Partners
    • SPA
    • SPPM
    • PALC
    • PCICS
    • AmSECT
    • SMACT
    • CHA
    • CCAN
  • Committees
    • CCAS Committees
      • Pediatric Cardiac Anesthesiology Program Director’s Group (PCAPD) Committee
      • Communications Committee
      • CCAS-STS Database Committee
      • Education Committee
      • Global Health Committee
      • Membership Committee
      • Quality and Safety Committee
      • Research Committee
    • CCAS Special Interest Groups
      • Adult Congenital Heart Disease Special Interest Group (SIG)
      • ERAS Special Interest Group (SIG)
      • Hemostasis Special Interest Group (SIG)
      • Latin America Special Interest Group (SIG)
      • Pulmonary Hypertension Special Interest Group (SIG)
      • Trainee Special Interest Group (SIG)
  • Membership
    • Benefits of Membership
    • CCAS Member App
    • Membership Categories
    • Join CCAS
      • Online Application
      • Printable Application
    • Renew Your Dues
    • Sponsor a Member
    • Get Involved
  • Meetings
    • Upcoming Meetings
    • Past Meetings
    • Other Meetings
    • Exhibit Information
  • Education
    • CCAS Virtual Visiting Professor Program
    • CCAS Webinar Series
      • CCAS Webinar Series – Recordings
    • CCAS COVID 19 Webinar
    • ACHD-SIG Anesthesia Rounds
    • Lecture Series
    • Echo Tutorial
    • Archived Questions
    • Poll of the Month Archives
    • Review Articles
      • CCAS-CHiP Network Journal Watch Collaboration
      • SCVA Articles
    • Journals of Interest
    • Books of Interest
    • Educational Links
  • Resources
    • CCAS Position Statements
    • CCAS Committee Resources
    • CCAS Special Interest Group (SIG) Resources
    • CCAS Cognitive Aids
    • Newsletters
    • Research Resources
    • Mission Trips
    • Societies
    • Job Opportunities
  • Research
    • Research Committee
    • CCAS 2025 Meeting Scholarship for Students and Residents
    • Research Network & Collaborative Opportunities
    • Research Resources
    • Dolly D. Hansen, MD Research Award
    • New for 2026! CCAS QI/Education Award
    • Podcast Series for Aspiring CCAS Researchers
    • Highlight on a CCAS Researcher
    • Call for Surveys
    • STS-CCAS Database
    • Donate to the Dolly Hansen Fund
  • Trainees
    • Introduction to Pediatric Cardiac Anesthesiology
    • Trainee Lecture Series
    • Advanced Training
    • Pediatric Cardiac Anesthesiology Fellowship Common Goals and Objectives
    • Frequently Asked Questions
    • Pediatric Cardiac Anesthesia Education Resources
    • Coaching/Mentoring Initiative
  • Patients
    • FAQs for Cardiac Anesthesia
    • FAQs for Cardiac Anesthesia – Spanish
    • SmartTots FAQs for Parents
    • Useful Resources for Parents

Question of the Week 536

Authors: Amy Babb, MD, AND Amanpreet Kalsi, MBBS, FRCA - Vanderbilt University Medical Center - Monroe Carell Jr. Children's Hospital at Vanderbilt

A 16-year-old female with a history of truncus arteriosus presents for RV-PA conduit change via sternotomy and cardiopulmonary bypass. She recently underwent a cardiac catheterization procedure for attempted percutaneous pulmonary valve placement and had severe post operative nausea and vomiting despite ondansetron and dexamethasone. Aprepitant is chosen for PONV prophylaxis after this surgery. What class of medication does aprepitant belong to?

Correct! Wrong!

EXPLANATION

Aprepitant is a neurokinin 1 receptor antagonist used to decrease the risk of nausea and vomiting in adults and children with chemotherapy-induced and post-operative nausea and vomiting (PONV). These drugs target receptors in both central and peripheral nervous systems. In the central nervous system, aprepitant crosses the blood brain barrier inihibiting g-protein coupled signals at the NK1 receptor. Inhibition at the NK1 receptors prevents substance P formation at multiple sites in the brain known to induce nausea and vomiting. In addition, NK1 receptors present in the peripheral nervous system and gut are inihibited by aprepitant leading to an overall deceased vomiting signal to the central nervous system.

Aprepitant can be given orally (tab or liquid) or intravenously. Fosaprepitant is a prodrug of aprepitant that is only available as an IV formulation. Dosing in pediatric patients is limited to the available prescribing information for chemotherapy-induced nausea and vomiting, with few studies describing pediatric patients receiving aprepitant for PONV. Consensus guidelines for PONV published in 2020 by Gan et al recommend a dose of aprepitant 40 mg PO given within 3 hours of anesthesia induction for adults and dosing of aprepitant 3 mg/kg up to 125 mg for PONV prophylaxis in children1.

A 2019 study evaluating noncardiac pediatric surgical patients from birth to 17 years demonstrated efficacy and safety for PONV with doses of 10 mg, 40 mg and 125 mg2. In 2023, Belk J, et al. described a single-center experience with preoperative aprepitant administration for pediatric cardiac surgical and catheterization patients with a history of severe PONV. This small subset of patients were older, with a mean age of 16 years, and received either 80 mg PO (if over 50 kg) and 40 mg PO (if less than 50 kg)3.

Described risks of aprepitant include decreased INR in patients taking warfarin as well as reduced efficacy of hormonal contraceptives for up to 28 days after administration4. As a general precaution, aprepitant is a weak inhibitor and inducer of CYP3A44. NK1 receptor antagonists have no effect on the QT interval, providing a potential advantage to its use in pediatric cardiac patients with risk factors for PONV. Multimodal management of PONV after pediatric cardiac surgery is an important aspect to any enhanced recovery protocol and NK1 receptor inhibitors may prove to be a useful addition.

REFERENCES

1. Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting Anesth Analg. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833

2. Salman FT, DiCristina C, Chain A, et al. Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. Journal of Pediatric Surgery. 2019; 54(7): 1384-1390. https://doi.org/10.1016/j.jpedsurg.2018.09.006.

3. Belk JW, Twite MD, Klockau KS, Silveira LJ and Clopton RG (2023) Effects of aprepitant on post-operative nausea and vomiting in patients with congenital heart disease undergoing cardiac surgery or catheterization procedures: a retrospective study with subjects as their own historical control. Front. Anesthesiol. 2023; 2:1190383. doi: 10.3389/fanes.2023.1190383

4. Merck & Co. Emend (Aprepitant). US Food and Drug Administration website. Issued July 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021549s012lbl.pdf

Poll of the Month

July 2025
In surgical cases with high post-bypass bleeding risk, what is your institution’s preferred initial rescue hemostatic agent following administration of standard blood products (e.g., platelets, cryoprecipitate, FFP)?
View Results
Total Answers 120
Total Votes 120

Upcoming Meeting Information


CCAS 2026 Annual Meeting

March 12, 2026
Sheraton Denver Downtown
Denver, CO

 

 

 

 

Join CCAS
Renew
Donate
Get Involved
Upcoming
Job Postings
  • Member Login
  • Forgot Password?
2209 Dickens Road, Richmond, VA 23230 • 804-282-9780 • [email protected]
Copyright © 2025 The Congenital Cardiac Anesthesia Society | View Privacy Policy